Cipla appoints Dr Raju Mistry as Global Chief People Officer

In her role at Cipla, Raju Mistry will oversee Human Resources, and Administration and Facilities Management. She will be a member of the Management Council of Cipla and will report to Umang Vohra, Managing Director & Global Chief Executive Officer.

Mumbai: Cipla Limited has announced the appointment of Dr Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla.

Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors such as Chemicals, Pharma, FMCG, IT, Engineering and Textiles.

Read Also: Cipla acquires 30 per cent stake in Brandmed for Rs 32 crore

Prior to joining Cipla, Raju was Chief Human Resources Officer (CHRO) at Jubilant Life Sciences Ltd. For 13 years before that, Raju led the talent, employer brand and leadership programmes of the Aditya Birla Group, and was CHRO of Grasim's Pulp and Fibre business. She has previously worked with Tata Sons, Colgate Palmolive, Siemens, and Mastech Corporation, Canada.

In her role at Cipla, Raju will oversee Human Resources, and Administration and Facilities Management. She will be a member of the Management Council of Cipla and will report to Umang Vohra, Managing Director & Global Chief Executive Officer.

Read Also: Cipla, Pulmatrix join hands to co-develop Pulmazole for treating asthma

Commenting on the appointment, Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla said: "We are delighted to welcome Raju to the Cipla family. In the last few years, Cipla has successfully worked towards strengthening its core, reiterating its values and focusing on building a future-ready organisation. Raju brings with her the experience to continue the journey and help us reach new milestones."

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in markets of India, South Africa, North America, and key regulated and emerging markets. The firm is strengthened in the respiratory, anti-retroviral, urology, cardiology and CNS segments.